PanCan, GeneCentric partner on precision medicine for pancreatic cancer

By staff writers

July 31, 2020 -- The Pancreatic Cancer Action Network (PanCan) and GeneCentric Therapeutics have partnered to conduct research on RNA-based molecular technologies to predict pancreatic cancer disease progression and drug response.

The partnership is designed to improve treatment response and survival rates of patients with pancreatic ductal adenocarcinoma (PDAC) tumors. It will utilize PanCan's patient molecular and outcomes data and GeneCentric's RNA-based portfolio, which includes the PurlSt profiler that identifies PDAC subtypes.

PanCan and GeneCentric will work together on two research projects for patients with basal and classical PDAC subtypes. In one project, researchers will perform a retrospective analysis of PanCan's Know Your Tumor Program data to study molecular characterization of potential treatment response.

In a second project, researchers will conduct a three-year study to investigate molecular signatures of patients enrolled in PanCan's Precision Promise clinical trial. Patients will have their molecular signatures assessed at enrollment, and researchers will study the association between immunogenomic signatures and treatment response.

AI predicts which patients to test for pancreatic cancer
Researchers created a model utilizing artificial intelligence (AI) that identified patients at an increased risk for pancreatic cancer who could benefit...
Broad genetic testing spots inherited mutations in young cancer patients
Younger adult cancer patients with tumors that more typically strike later in life may benefit from genetic testing to pick up on germline mutations,...
Blood test bolsters imaging for staging pancreatic cancer
A multianalyte blood test was useful for diagnosing and staging pancreatic ductal adenocarcinoma, adding information beyond what is available from imaging...
How to manage genetic testing of pancreatic cancer patients
With momentum growing for germline testing of all patients newly diagnosed with pancreatic cancer, experts published a road map in JAMA Oncology...
Lynparza PARP approval opens door to more pancreatic cancer testing
Approval of the drug olaparib (Lynparza, Merck/AstraZeneca) by the U.S. Food and Drug Administration at the end of 2019 paves the way for more testing...

Copyright © 2020

Last Updated ls 7/31/2020 8:58:38 AM